In summary, our findings highlight the potential of transcriptional activity, particularly TBX21 activation, as a biomarker for the efficacy of efgartigimod in treating MG, attributed to the central role of T‐bet+ B cells in pathogenic IgG production and antigen presentation. Here, TBX21 is linked to myasthenia gravis.